"Ribavirin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
Descriptor ID |
D012254
|
MeSH Number(s) |
D13.570.800.790
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ribavirin".
Below are MeSH descriptors whose meaning is more specific than "Ribavirin".
This graph shows the total number of publications written about "Ribavirin" by people in this website by year, and whether "Ribavirin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
2004 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2007 | 1 | 1 | 2 |
2008 | 1 | 0 | 1 |
2010 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ribavirin" by people in Profiles.
-
Bader T, Hughes LD, Fazili J, Frost B, Dunnam M, Gonterman A, Madhoun M, Aston CE. A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients. J Viral Hepat. 2013 Sep; 20(9):622-7.
-
Romero-Gomez M, Eslam M, Ruiz A, Maraver M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int. 2011 Apr; 31(4):443-60.
-
Fazili J, Mallonee S, Tierney WM, Bader TF, Sachdev AK, Bird PC, Schmidt RD, Mesiya SA, Lackey CL. Outcome of a hepatitis C outbreak among patients in a pain management clinic. Dig Dis Sci. 2010 Jun; 55(6):1738-43.
-
Le V, Bader T, Fazili J. A case of hearing loss associated with pegylated interferon and ribavirin treatment ameliorated by prednisone. Nat Clin Pract Gastroenterol Hepatol. 2009 Jan; 6(1):57-60.
-
Yeh WS, Armstrong EP, Skrepnek GH, Malone DC. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System. Pharmacotherapy. 2007 Jun; 27(6):813-24.
-
Gleason OC, Fucci JC, Yates WR, Philipsen MA. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study. Dig Dis Sci. 2007 Oct; 52(10):2557-63.
-
Chávez-Bueno S, Mejías A, Welliver RC. Respiratory syncytial virus bronchiolitis : current and future strategies for treatment and prophylaxis. Treat Respir Med. 2006; 5(6):483-94.
-
Armor JF, Fazili J, Toubia N, Kern W, Kamble R, Kharfan-Dabaja MA. Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy. Am J Hematol. 2005 Mar; 78(3):212-5.
-
Welliver RC. Respiratory syncytial virus infection: therapy and prevention. Paediatr Respir Rev. 2004; 5 Suppl A:S127-33.
-
Rodriguez WJ, Hall CB, Welliver R, Simoes EA, Ryan ME, Stutman H, Johnson G, Van Dyke R, Groothuis JR, Arrobio J, et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr. 1994 Jul; 125(1):129-35.